5Definitions

5 Definitions

Note: A number of expressions used in this instrument are defined in the Act, including the following:

(a) designated vaccine;
(b) Secretary;
(c) vaccine.

In this instrument:

Act means the National Health Act 1953.

amount includes a nil amount.

approved ex‑manufacturer price has the meaning given by subsection 84(1) of the Act.

ATAGI means the Commonwealth body known as the Australian Technical Advisory Group on Immunisation.

ATAGI advice has the meaning given by subsection 7(1).

ATAGI application has the meaning given by subsection 7(1).

ATAGI application due day has the meaning given by subsection 10(3).

Australian Register of Therapeutic Goods means the register maintained under section 9A of the Therapeutic Goods Act 1989.

brand has the meaning given by subsection 84(1) of the Act.

Committee means the Pharmaceutical Benefits Advisory Committee established under section 100A of the Act.

complex category ATAGI application fee has the meaning given by subsection 7(2).

cost‑effectiveness test means an assessment of:

(a) the extent (if any) to which the efficacy and toxicity of the therapy proposed in a submission for a disease or disorder differs from the efficacy and toxicity of any alternative therapy for the disease or disorder; and
(b) the cost of the proposed therapy relative to the cost of the alternative therapy.

designated orphan drug has the same meaning as in the Therapeutic Goods Regulations 1990.

economic evaluation, for a submission and a drug, medicinal preparation or vaccine the subject of the submission, means data that is a comparative analysis of the costs and outcomes of:

(a) the therapy to be provided by the drug, medicinal preparation or vaccine; and
(b) any other therapy that the applicant nominates as an alternative therapy to the drug, medicinal preparation or vaccine.

evaluation category means an evaluation category referred to in the table in subsection 22(2).